A carregar...
Identifying patients with NTRK fusion cancer
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer. These oncogenic fusions...
Na minha lista:
| Publicado no: | Ann Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859817/ https://ncbi.nlm.nih.gov/pubmed/31738428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz384 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|